The IBTA is delighted and proud to be a partner organisation for the exciting GLIOTRAIN project

By 13th March 2018 March 29th, 2018 IBTA News


[13th March 2018] New treatment options and effective precision medicine therapies are urgently required for glioblastomas (GBMs), a highly malignant and aggressive type of brain tumour. GBMs are the most common high grade (cancerous) primary brain tumours in adults. GLIOTRAIN is a multi-sectoral industry-academia collaboration, funded by the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie ITN initiative, that will work to identify novel strategies to treat GBM as well as investigating resistance mechanisms in this devastating disease.

Click image to read an explanatory GLIOTRAIN flyer

The GLIOTRAIN consortium (launched in September 2017) comprises 23 international organisations including leading international academics, clinicians, private sector and not-for-profit partners across the fields of brain tumour biology, multi-omics, drug development, clinical research, bioinformatics, computational modelling and systems biology.

Fifteen GLIOTRAIN sub-projects split into two scientific work packages will employ systems medicineintegrative multi-'omics and translational cancer biology platforms accessing clinically relevant models and patient data-sets. GLIOTRAIN will identify and interrogate novel therapeutic strategies for application in GBM, while simultaneously implementing state of the art next generation sequencing to unravel disease resistance mechanisms. The programme will implement systems-based analysis of known contributors of disease progression, as well as perform unbiased molecular profiling and computational modelling.

Work Package 1 (WP1) – GLIOTREAT

There are 8 sub-projects in this WP, which is lead by the Royal College of Surgeons in Ireland. Other parties involved are the University of Stuttgart, Cancer Trials Ireland, In Silico Biotechnology, Yumab, ICM Institute for Brain and Spinal Cord, CarThera, VIB, Champions Oncology, Oncurious, Agilent Technologies, Erasmus University Medical Center and Teva Pharmaceutical Industries.

WP Objective: New treatment strategies are urgently required to circumvent GBM disease 'fetters'. GLIOTRAIN will address this urgent issue using innovative approaches within WP1 underpinned by innovative systems medicine and/or integrative 'omic approaches and applying state-of-the-art disease models and drug delivery methods.

Work Package 2 (WP2) – GLIORESIST

There are 7 sub-projects in this WP which is lead by Vlaams Instituut for Biotechnology, Leuven. Other parties involved are the Royal College of Surgeons in Ireland, GeneXplain, ICM Institute for Brain and Spinal Cord, Luxembourg Institute of Health, ITTM, Agilent Technologies, Erasmus University Medical Center, Pepscope and Mimetas.

WP Objective: Intratumoural heterogeneity and cancer evolution contribute to therapy resistance and tumour aggressiveness. The mechanisms underpinning GBM inter/intra-tumoural heterogeneity and therapy resistance are not well understood. Thus, innovative in silico models, implementation of the newest 'omic platform technologies and new computational and integrative data analysis methods will be employed in WP2, (GLIORESIST) to interrogate these mechanisms.


The first GLIOTRAIN training event will take place at the Royal College of Surgeons in Ireland, Dublin from the 23rd to the 26th April 2018. It will be the first time all Early Stage Researchers (ESRs) will meet together. There will be an interaction day with all Principle Investigators (PIs) and ESRs to familiarise the students with the programme. . IBTA Co-Director Kathy Oliver will be leading a mini-symposium at this training meeting, whereby GLIOTRAIN students will have the opportunity to consider the "bigger picture" impact of their research and to reflect on how GLIOTRAIN findings may ultimately impact patients. Key topics such as research project management, open science and data management will also be covered at this event.

let us know you agree to cookies

The IBTA website uses cookies to give you the best online experience in accordance with our cookies policy. If you are happy, please confirm by clicking the 'Accept' button below.